Accepted Manuscript



Mutational analysis of the extracellular disulphide bridges of the atypical chemokine receptor ACKR3/CXCR7 uncovers multiple binding and activation modes for its chemokine and endogenous non-chemokine agonists

Martyna Szpakowska, Max Meyrath, Nathan Reynders, Manuel Counson, Julien Hanson, Jan Steyaert, Andy Chevigné

PII: S0006-2952(18)30096-0
DOI: https://doi.org/10.1016/j.bcp.2018.03.007
Reference: BCP 13084

To appear in: *Biochemical Pharmacology*

Received Date: 11 February 2018
Accepted Date: 7 March 2018

Please cite this article as: M. Szpakowska, M. Meyrath, N. Reynders, M. Counson, J. Hanson, J. Steyaert, A. Chevigné, Mutational analysis of the extracellular disulphide bridges of the atypical chemokine receptor ACKR3/CXCR7 uncovers multiple binding and activation modes for its chemokine and endogenous non-chemokine agonists, *Biochemical Pharmacology* (2018), doi: https://doi.org/10.1016/j.bcp.2018.03.007

Mutational analysis of the extracellular disulphide bridges of the atypical chemokine receptor ACKR3/CXCR7 uncovers multiple binding and activation modes for its chemokine and endogenous non-chemokine agonists

Martyna Szpakowska[1,2,Ψ], Max Meyrath[1,Ψ], Nathan Reynders[1,3], Manuel Counson[1], Julien Hanson[4], Jan Steyaert[2] and Andy Chevigné[1*]

[1] Department of Infection and Immunity, Immuno-Pharmacology and Interactomics, Luxembourg Institute of Health (LIH), L-4354 Esch-sur-Alzette, Luxembourg

[2] Structural Biology Brussels, Vrije Universiteit Brussel, B-1050 Brussels, Belgium

[3] Faculty of Science, Technology and Communication, University of Luxembourg, L-4365 Esch-sur-Alzette, Luxembourg

[4] Laboratory of Molecular Pharmacology, GIGA-Molecular Biology of Diseases, GIGA B34, University of Liège, 11 Avenue de l'Hôpital, B-4000, Liège, Belgium

Short title:

Atypical presence and function of disulphide bridges in ACKR3/CXCR7

Keywords: chemokine receptor, CXCR7, ACKR3, CXCR4, BAM22, CXCL12, adrenomedullin

[Ψ]Both authors contributed equally

***** To whom correspondence should be addressed: Dr. Andy Chevigné, Immuno-Pharmacology and Interactomics, Department of Infection and Immunity, Luxembourg Institute of Health (LIH), 29, rue Henri Koch, L-4354 Esch-sur-Alzette, Luxembourg. Tel: +352 26970-336; Email: andy.chevigne@lih.lu